Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.

BMC Cancer · 2019 · PMC6849282 · PMID 31718608

Europe PMC DOI

hedged sentences

0.1060

closest p · 2.1× alpha

0.1060

boldest claim

The sentences

showed a trendp = 0.106not close (p > 0.1)

Although there were no statistical differences, Kaplan-Meier analyses showed a trend that RFS in patients with high serum FGF19 levels (≥200 pg/mL) is shorter than those in patients with low serum FGF19 levels ( p = 0.106, Fig. 5 a).

also in 53,322 other papers

an increasing trendno p-value reported

Although the sensitivities of AFP and DCP were 29.1 and 44.7% in HCC with UICC stage I, respectively, there was an increasing trend with stage progression.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.